Telix Pharmaceuticals Ltd. has announced the successful production and delivery of its first Good Manufacturing Practice $(GMP.UK)$-grade commercial radiopharmaceutical doses from its Telix Manufacturing Solutions facility in Brussels South, Belgium. This milestone marks the expansion of Telix's commercial radiopharmacy capabilities in Europe. The facility, which is one of the largest in Europe, features nine GMP lines, clean rooms, a radiopharmacy, and two cyclotrons. This advancement allows Telix to provide GMP-grade products and radiolabelling services, enhancing access to radiopharmaceuticals in Belgium and beyond. The move is expected to significantly impact patient care, particularly in cancer treatment, while supporting future production of important isotopes and radiopharmaceuticals.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.